Please assess the completion status of the following clinical trial:

Trial Title: Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients underwent to PCI~* lopidogrel resistance after Platelet reactivity blood test~Exclusion Criteria:~* history of bleeding diathesis~* chronic oral anticoagulation treatment~* contraindications to antiplatelet therapy~* PCI or coronary artery bypass grafting (CABG) \<3 months~* hemodynamic instability~* platelet count \<100,000/μl~* hematocrit \<30%~* creatinine clearance \<25 ml/min~* Patients with a history of stroke~* contraindication for prasugrel administration~* patients weighing \<60 kg~* \>75 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- high clopidogrel dose (Type: ACTIVE_COMPARATOR): Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
- prasugrel standard dose (Type: NO_INTERVENTION): Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).